06/29/2017

FDA approved RITUXAN HYCELA™ (rituximab and hyaluronidase human) for subcutaneous injection for the treatment of certain adult cancer.

The FDA approved RITUXAN HYCELA™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukemia (CLL). This new treatment includes the same monoclonal antibody as intravenous Rituxan^® (rituximab) in combination with hyaluronidase human, an enzyme that helps to deliver rituximab under the skin.

Rituxan Hycela Billing & Coding Flashcard

For more information, click here.